MARK1
| Official symbol: | MARK1 |
| Full name: | microtubule affinity regulating kinase 1 |
| Location: | 1q41 |
| Also known as: | PAR-1C, MARK |
| Entrez ID: | 4139 |
| Ensembl ID: | ENSG00000116141 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.00 |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 2 |
|
|
| Fusions detected in 2 cancer type(s) |
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
RNAi: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 56.11 (Percentile rank: 64.28%) |
| PubTator score: | 844.23 (Percentile rank: 95.85%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
